CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
30. September 2024 19:07 ET
|
Clinuvel Pharmaceuticals Limited
CLINUVEL has filed a Canadian New Drug Submission for SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP).
Afamelanotide in fair-skinned Parkinson’s patients
17. Juni 2024 20:39 ET
|
Clinuvel Pharmaceuticals Limited
CLINUVEL has launch a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease in fair-skinned patients.
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
28. März 2024 04:25 ET
|
Clinuvel Pharmaceuticals Limited
Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing in Dusseldorf, Germany.
CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
01. Februar 2023 19:14 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical study have shown that the drug afamelanotide can reduce critical skin damage caused by ultraviolet (UV)...
CLINUVEL Trial Results Show Drug Reduces DNA Damage
15. Januar 2023 18:23 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of...
CLINUVEL progresses vitiligo treatment program
09. Mai 2022 21:33 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug afamelanotide...
Positive final results in stroke
03. Mai 2022 20:24 ET
|
Clinuvel Pharmaceuticals Limited
ASX: XETRA-DAX: Level 1 ADR:CUV UR9 CLVLY EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6)NIHSS1 scores improved in five...
CLINUVEL to Trial Innovative Drug in Stroke
27. Oktober 2020 18:50 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of...
First patient dosed in SCENESSE® DNA Repair Program
15. September 2020 03:31 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment Note to editors: CLINUVEL is releasing in-depth infographics and a video...
CLINUVEL progresses innovative DNA Repair Program
10. September 2020 03:18 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced the progression of its drug SCENESSE® (afamelanotide 16mg) to treat the disease xeroderma...